Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis

Chen,Wei; Liu,Yi; Chen,Hongde; Ning,Hao; Ding,Kejia

doi:10.3892/ijo.2017.4038

Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis

Authors:
- Wei Chen
- Yi Liu
- Hongde Chen
- Hao Ning
- Kejia Ding
View Affiliations

Affiliations: Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: June 12, 2017 https://doi.org/10.3892/ijo.2017.4038
Pages: 435-444
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Distant metastasis is the worst prognostic factor for PCa patients. It has been reported that miR-449a enhances radiosensitivity of prostate cancer cells, but the function of miR449a in metastasis of prostate cancer is mainly unknown. In the present study, we strove to investigate the function and diagnostic value of miR-449a in metastasis of prostate cancer. qRT-PCR was used to quantify the expression of miR449a and PrLZ in PCa cell lines and tissues. we found that miR449a expression was decreased in PCa cell lines. Moreover, miR‑449a was downregulated in PCa tissues, especially in primary lesion tissues of metastatic PCa patients. CCK8, FACS, transwell and tube formation assay were performed to assess growth and metastasis of PCa cells in vitro. Lentivirus mediated miR-449a overexpression suppressed proliferation of LNcap and PC-3, and miR-449a also significantly inhibited invasion and angiogenesis ability of LNcap and PC-3. IHC showed that PrLZ was upregulated in PCa tissues. Luciferase assay and western blotting verified that miR-449a targeted PrLZ expression. Moreover, PrLZ shRNA also significantly suppressed proliferation and metastasis of LNcap and PC-3. In addition, western blotting revealed that miR-449a overexpression and PrLZ shRNA all remarkably inhibited the stemness features in LNcap and PC-3. Furthermore, BALB/c nude mouse subcutaneous xenograft model was uesd to verify the function of miR-449a and PrLZ. Our results showed that miR-449a and PrLZ shRNA significantly suppressed PC-3 tumorigenesis and metastasis in vivo. Our studies suggested that miR-449a decreased in malignant process of PCa and was accompanied by excess expression of PrLZ. The loss of miR-449a caused PrLZ overexpression regulated prostate cancer progression and metastasis via regulating the stemness features of prostate cancer cells. The diagnostic value of miR-449a as a distant metastasis predictor of PCa needs further investigation.

View Figures

View References

1	Adisa JO, Egbujo EC, Ibrahim B, Musa B and Madukwe J: Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: Can these be used as tumor markers. Pan Afr Med J. 20:462015. View Article : Google Scholar : PubMed/NCBI
2	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
3	Qi JL, Wang LJ, Zhou MG, Liu YN, Liu JM, Liu SW, Zeng XY and Yin P: Disease burden of prostate cancer among men in China from 1990 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 37:778–782. 2016.In Chinese. PubMed/NCBI
4	Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1591–1597. 1999. View Article : Google Scholar : PubMed/NCBI
5	Logothetis CJ and Lin SH: Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 5:21–28. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, Ichihara K, Yonese J, Koizumi M, Nakashima J, et al: Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer. 94:964–972. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, Miyake M, Hirayama A, Hasegawa M and Hirao Y: Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis. Jpn J Clin Oncol. 41:1209–1213. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lilleby W and Fosså SD: Chemotherapy in metastatic renal cell cancer. World J Urol. 23:175–179. 2005. View Article : Google Scholar : PubMed/NCBI
9	Todorova K, Metodiev MV, Metodieva G, Zasheva D, Mincheff M and Hayrabedyan S: miR-204 is dysregulated in metastatic prostate cancer in vitro. Mol Carcinog. 55:131–147. 2016. View Article : Google Scholar
10	Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F, Chen WY and Liu YN: Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene. 34:4767–4776. 2015. View Article : Google Scholar
11	Browne G, Taipaleenmäki H, Stein GS, Stein JL and Lian JB: MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 25:320–327. 2014. View Article : Google Scholar : PubMed/NCBI
12	Abba M, Patil N, Leupold JH and Allgayer H: MicroRNAs - from metastasis prediction to metastasis prevention? Mol Cell Oncol. 3:e10743362015. View Article : Google Scholar
13	Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J, Amin M, He D, Marshall FF, Zhau HE and Chung LW: PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res. 13:6040–6048. 2007. View Article : Google Scholar : PubMed/NCBI
14	Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, Wang X and He D: PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol Carcinog. 48:432–440. 2009. View Article : Google Scholar
15	Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, et al: Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis. 34:257–267. 2013. View Article : Google Scholar :
16	Upile T, Jerjes W, Radhi H, Al-Khawalde M, Kafas P, Nouraei S and Sudhoff H: Vascular mimicry in cultured head and neck tumour cell lines. Head Neck Oncol. 3:552011. View Article : Google Scholar : PubMed/NCBI
17	Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC, Agarwal C and Agarwal R: SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer. 13:372014. View Article : Google Scholar : PubMed/NCBI
18	Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS and Keller J: New trends in the treatment of bone metastasis. J Cell Biochem. 102:1095–1102. 2007. View Article : Google Scholar : PubMed/NCBI
19	Weidle UH, Birzele F, Kollmorgen G and Rüger R: Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics. 13:1–12. 2016.
20	Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ and Chakravarti A: Circulating microRNAs in cancer: Hope or hype? Cancer Lett. 381:113–121. 2016. View Article : Google Scholar : PubMed/NCBI
21	White NM, Fatoohi E, Metias M, Jung K, Stephan C and Yousef GM: Metastamirs: A stepping stone towards improved cancer management. Nat Rev Clin Oncol. 8:75–84. 2011. View Article : Google Scholar
22	Ell B and Kang Y: MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014. View Article : Google Scholar : PubMed/NCBI
23	Chen SP, Liu BX, Xu J, Pei XF, Liao YJ, Yuan F and Zheng F: MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets. BMC Cancer. 15:7062015. View Article : Google Scholar : PubMed/NCBI
24	Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One. 8:e647592013. View Article : Google Scholar : PubMed/NCBI
25	Li Q, Peng J, Li X, Leng A and Liu T: miR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-β-mediated EMT. Diagn Pathol. 10:2022015. View Article : Google Scholar
26	Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C and Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 28:1714–1724. 2009. View Article : Google Scholar : PubMed/NCBI
27	Mao A, Zhao Q, Zhou X, Sun C, Si J, Zhou R, Gan L and Zhang H: MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cells. Sci Rep. 6:273462016. View Article : Google Scholar : PubMed/NCBI
28	Graff JR and Zimmer SG: Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003. View Article : Google Scholar : PubMed/NCBI
29	Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC and Sanderson RD: Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res. 65:5778–5784. 2005. View Article : Google Scholar : PubMed/NCBI
30	Miyamoto N, Yamamoto H, Taniguchi H, Miyamoto C, Oki M, Adachi Y, Imai K and Shinomura Y: Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability. Cancer Lett. 254:42–53. 2007. View Article : Google Scholar : PubMed/NCBI
31	Perlikos F, Harrington KJ and Syrigos KN: Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, et al: The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 66:1012–1021. 2017. View Article : Google Scholar : PubMed/NCBI
33	Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, et al: PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res. 67:8906–8913. 2007. View Article : Google Scholar : PubMed/NCBI
34	Nakazawa M and Kyprianou N: Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. J Steroid Biochem Mol Biol. 166:84–90. 2017. View Article : Google Scholar
35	Diepenbruck M and Christofori G: Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
36	Kim EK, Choi EJ and Debnath T: Role of phytochemicals in the inhibition of epithelial-mesenchymal transition in cancer metastasis. Food Funct. 7:3677–3685. 2016. View Article : Google Scholar : PubMed/NCBI